Health
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm. Additional data presented from the Phase 3 VIVID-1 (Crohn's disease) and LUCENT-3 (UC) clinical trials showed Omvoh-treated patient
About this update from Eli Lilly And Company
[{"type":"text","content":"Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years ","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory ","length":237,"tagName":"p","attribs":{}},{"type":"text","content":"Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's disease","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm. Additional data presented from the Phase 3 VIVID-1 (Crohn's disease) and LUCENT-3 (UC) clinical trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease (IBD).2,3 Omvoh is the first and only IL-23p19 inhibitor to show strong and durable efficacy over four years in UC and three years in Crohn's disease, with proven reduction of disease complications.","length":865,"tagName":"p"},{"type":"text","content":""Too many people with inflammatory bowel disease never achieve lasting remission, leaving them vulnerable to cumulative damage from poorly controlled inflammation that can result in emergency hospitalizations or surgery," said Adrienne Brown, executive vice president and president of Lilly Immunology. "Omvoh is redefining what durable disease control can look like, with long-term data showing patients treated with Omvoh stayed in remission and experienced fewer serious complications over three years, underscoring its potential to alter the course of the disease."","length":589,"tagName":"p"},{"type":"text","content":"Long-Term ...